FIELD: pharmaceutical industry.
SUBSTANCE: group of inventions relates to a mucoadhesive composition and a method of treating one or more inflammatory conditions of the esophagus, eosinophilic esophagitis or inflammatory bowel disease. A mucoadhesive pharmaceutical composition based on a corticosteroid containing the following ingredients: (a) budesonide in an amount of 0.02–0.06 wt./wt.% of the composition, (b) glycerin in an amount of 40–70 wt./wt.% of the composition, (c) xanthan gum in an amount of 0.25–1.5 wt./wt.% of the composition, and (d) propylene glycol in an amount of not more than 20 wt./wt.% of the composition, the composition having a pH of 4.5 to 7. A method of treating one or more inflammatory conditions of the esophagus, eosinophilic esophagitis or inflammatory bowel disease, comprising administering the above-described composition to a subject in need thereof.
EFFECT: above composition characterized by good mucoadhesive properties and stability, has local activity and prevents unwanted systemic effects by minimizing the penetration of the active ingredient through the mucous membrane.
15 cl, 8 dwg, 5 ex, 7 tbl
Title | Year | Author | Number |
---|---|---|---|
CORTICOSTEROID COMPOSITIONS | 2008 |
|
RU2491074C2 |
LIQUID PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION BASED ON AMINOSALICYLATES | 2019 |
|
RU2804487C2 |
LIQUID COMPOSITIONS CONTAINING MUCOADHESIVE AGENT | 2017 |
|
RU2773140C2 |
TREATMENT OF MUCOSAL DAMAGES USING HYALURONAN DELIVERED FROM ADHERING LOZENGE | 2014 |
|
RU2693384C2 |
ION EXCHANGE COMPOSITION WITH WATER-SOLUBLE MUCOADHESIVE POLYMERS | 2020 |
|
RU2812603C1 |
AQUEOUS ORAL CARE COMPOSITION | 2011 |
|
RU2609862C2 |
RECTAL FOAM COMPOSITIONS | 2017 |
|
RU2757275C2 |
ORAL CARE COMPOSITIONS | 2021 |
|
RU2757224C1 |
CONTROLLED SUPERFICIAL GEL-GENERATION OF MUCOADHESIVE POLYMERS IN ORAL CAVITY MUCOSA | 2008 |
|
RU2440809C2 |
THE COMPOSITION OF FENFLURAMINE, COMPATIBLE WITH A KETOGENIC DIET | 2018 |
|
RU2778848C2 |
Authors
Dates
2023-10-24—Published
2019-10-23—Filed